Compare Stocks: RGNX, RARE, PGEN, and BCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$9.96 -1.3%	$9.75	$6.00 ▼ $11.22	$2.55B	0.57	2.87 million shs	1.48 million shs
PGEN Precigen	$7.10 -0.6%	$6.20	$2.99 ▼ $7.72	$2.53B	1.02	4.84 million shs	2.19 million shs
RARE Ultragenyx Pharmaceutical	$15.30 +3.0%	$27.76	$13.81 ▼ $39.89	$1.51B	0.31	3.99 million shs	11.48 million shs
RGNX REGENXBIO	$8.94 -2.8%	$11.01	$5.45 ▼ $16.19	$590.16M	0.94	1.27 million shs	1.07 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	+1.43%	+7.10%	+18.43%	+20.14%
PGEN Precigen	0.00%	+2.16%	+2.75%	+98.32%	+49.47%
RARE Ultragenyx Pharmaceutical	0.00%	-40.26%	-40.74%	-30.17%	-51.51%
RGNX REGENXBIO	0.00%	-7.45%	-20.74%	+47.04%	-9.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$9.96 -1.3%	$9.75	$6.00 ▼ $11.22	$2.55B	0.57	2.87 million shs	1.48 million shs
PGEN Precigen	$7.10 -0.6%	$6.20	$2.99 ▼ $7.72	$2.53B	1.02	4.84 million shs	2.19 million shs
RARE Ultragenyx Pharmaceutical	$15.30 +3.0%	$27.76	$13.81 ▼ $39.89	$1.51B	0.31	3.99 million shs	11.48 million shs
RGNX REGENXBIO	$8.94 -2.8%	$11.01	$5.45 ▼ $16.19	$590.16M	0.94	1.27 million shs	1.07 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	+1.43%	+7.10%	+18.43%	+20.14%
PGEN Precigen	0.00%	+2.16%	+2.75%	+98.32%	+49.47%
RARE Ultragenyx Pharmaceutical	0.00%	-40.26%	-40.74%	-30.17%	-51.51%
RGNX REGENXBIO	0.00%	-7.45%	-20.74%	+47.04%	-9.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.67	Moderate Buy	$20.60	106.83% Upside
PGEN Precigen	2.80	Moderate Buy	$14.50	104.23% Upside
RARE Ultragenyx Pharmaceutical	2.52	Moderate Buy	$36.63	139.42% Upside
RGNX REGENXBIO	2.62	Moderate Buy	$23.27	160.32% Upside

Current Analyst Ratings Breakdown

Latest RGNX, RARE, PGEN, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	RARE Ultragenyx Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$28.00 ➝ $19.00
9/4/2026	RARE Ultragenyx Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$43.00 ➝ $32.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
9/3/2026	RARE Ultragenyx Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$77.00 ➝ $28.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $28.00
9/3/2026	RARE Ultragenyx Pharmaceutical	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$49.00 ➝ $18.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/3/2026	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$30.00 ➝ $23.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$83.00 ➝ $37.00
9/3/2026	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/27/2026	BCRX BioCryst Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$874.84M	2.91	$1.24 per share	8.04	($0.57) per share	-17.47
PGEN Precigen	$9.68M	261.49	N/A	N/A	$0.06 per share	118.33
RARE Ultragenyx Pharmaceutical	$673M	2.24	N/A	N/A	($0.83) per share	-18.43
RGNX REGENXBIO	$170.44M	3.46	N/A	N/A	$2.03 per share	4.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	$263.86M	-$1.50	N/A	13.83	N/A	-40.90%	-86.89%	66.37%	11/2/2026 (Estimated)
PGEN Precigen	-$250.64M	-$1.04	N/A	8.26	N/A	-183.98%	423.75%	84.39%	11/12/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)
RGNX REGENXBIO	-$193.88M	-$3.79	N/A	N/A	N/A	-112.58%	-220.07%	-46.04%	11/5/2026 (Estimated)

Latest RGNX, RARE, PGEN, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	RGNX REGENXBIO	$0.0787	$0.43	+$0.3513	$0.43	$97.63 million	$108.02 million
8/5/2026	Q2 2026	BCRX BioCryst Pharmaceuticals	$0.1542	$0.30	+$0.1458	$0.30	$183.28 million	$218.25 million
8/4/2026	Q2 2026	PGEN Precigen	-$0.0121	$0.05	+$0.0621	$0.05	$27.98 million	$54.98 million
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.32	2.29
PGEN Precigen	2.15	4.58	3.89
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56
RGNX REGENXBIO	N/A	2.86	2.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
PGEN Precigen	33.51%
RARE Ultragenyx Pharmaceutical	97.67%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	3.80%
PGEN Precigen	41.40%
RARE Ultragenyx Pharmaceutical	5.20%
RGNX REGENXBIO	14.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	255.54 million	245.83 million	Optionable
PGEN Precigen	190	356.51 million	208.92 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable
RGNX REGENXBIO	370	66.01 million	56.63 million	Optionable

RGNX, RARE, PGEN, and BCRX Headlines

Recent News About These Companies

Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome

September 4 at 8:51 PM | insidermonkey.com

Corient Private Wealth LP Purchases New Stake in REGENXBIO Inc. $RGNX

September 3 at 3:44 AM | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Trading Down 4.8% - Time to Sell?

August 31, 2026 | marketbeat.com

6,397,440 Shares in REGENXBIO Inc. $RGNX Bought by BlackRock Inc.

August 31, 2026 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts

August 29, 2026 | americanbankingnews.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 29, 2026 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Shares Gap Up - Still a Buy?

August 28, 2026 | marketbeat.com

Deutsche Bank AG Invests $2.49 Million in REGENXBIO Inc. $RGNX

August 28, 2026 | marketbeat.com

REGENXBIO Director Gregory Ciongoli Discloses Multiple Stock Purchases and Option Grant in August 2026

August 28, 2026 | kalkinemedia.comK

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Ansell (OtherANSLF)

August 27, 2026 | theglobeandmail.com

HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

August 27, 2026 | americanbankingnews.com

Robert W. Baird Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

August 27, 2026 | americanbankingnews.com

Ieq Capital LLC Buys Shares of 141,469 REGENXBIO Inc. $RGNX

August 26, 2026 | marketbeat.com

Regenxbio’s RGX-121 setback carries a potential cash risk, warns Clear Street

August 26, 2026 | msn.com

Regenxbio: Sell-Off On Hunter Setback Presents A Risky Buy Opportunity

August 26, 2026 | seekingalpha.com

RegenXBio reshapes board with new independent director

August 25, 2026 | tipranks.com

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

August 25, 2026 | businesswire.com

REGENXBIO (NASDAQ:RGNX) Shares Up 7.5% - Here's Why

August 25, 2026 | marketbeat.com

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

August 25, 2026 | zacks.com

REGENXBIO (NASDAQ:RGNX) Price Target Lowered to $21.00 at HC Wainwright

August 25, 2026 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Price Target Cut to $29.00 by Analysts at Robert W. Baird

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, RARE, PGEN, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.96 -0.13 (-1.29%)

As of 09/4/2026 04:00 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Precigen NASDAQ:PGEN

$7.10 -0.04 (-0.56%)

As of 09/4/2026 04:00 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Ultragenyx Pharmaceutical NASDAQ:RARE

$15.30 +0.45 (+3.03%)

As of 09/4/2026 04:00 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

REGENXBIO NASDAQ:RGNX

$8.94 -0.26 (-2.83%)

As of 09/4/2026 04:00 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGNX, RARE, PGEN, and BCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGNX, RARE, PGEN, and BCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGNX, RARE, PGEN, and BCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, RARE, PGEN, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

Precigen NASDAQ:PGEN

Ultragenyx Pharmaceutical NASDAQ:RARE

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGNX, RARE, PGEN, and BCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGNX, RARE, PGEN, and BCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGNX, RARE, PGEN, and BCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, RARE, PGEN, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

Precigen NASDAQ:PGEN

Ultragenyx Pharmaceutical NASDAQ:RARE

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools